Santos and his colleagues have recently identified a small mitochondrial uncoupler, named BAM15, that holds promise for future treatment and prevention of obesity, diabetes, and especially nonalcoholic steatohepatitis, a type of fatty liver disease.
The Virginia Tech Center for Drug Discovery will host a May 21-22 meeting of the Virginia Drug Discovery Consortium to be held at the Hotel Roanoke, with such topics as opioid abuse, addiction, and data science in medicine as topics.
Webster Santos, professor of chemistry and the Cliff and Agnes Lilly Faculty Fellow in the College of Science at Virginia Tech, recently received a $2.8 million award from the National Institute of Allergy and Infectious Diseases to discover drugs to inhibit a small molecule transporter.
“We hope this new insight on the druggable surface of HIV will provide routes to novel types of therapeutics to combat this virus that has taken so many lives,” said Anne M. Brown, an assistant professor in research and informatics in University Libraries and an adjunct professor in the Department of Biochemistry in the College of Agriculture and Life Sciences.
Santos is a member of the Virginia Tech Center for Drug Discovery and the Virginia Drug Discovery Consortium, and is an expert medicinal chemist whose research focuses on compounds with new modes of action to treat kidney fibrosis, fatty liver disease, neurodegenerative diseases, traumatic brain injury, stroke, and aging.
Two naturally occurring compounds —
identified in the small molecule library available at the Virginia Tech Center for Drug Discovery Screening Laboratory supported by the Fralin Life Science Institute — work against an enzyme important in cell wall production in the deadly fungus, called Aspergillus fumigatus.
Scott Verbridge, assistant professor in the Department of Biomedical Engineering and Mechanics, is working on an innovative cancer treatment using the physical properties of tumors as effective alternative targets for next-generation therapies.
Associate Professor David Brown teamed with scientists from across the U.S. and Europe on a research project that could lead to new approaches for treating the No. 1 killer among men and women worldwide.
A Virginia Tech chemist is investigating how inhibiting an enzyme could be used as therapy for a multitude of diseases, including cancer, chronic kidney disease, sickle cell disease, and parasite infections.